Functional and Clinical Impact of CYP3A Genetic Polymorphisms on Statin Therapy

Withdrawn

• Conditions: Patients With High Cholesterol Levels Needing a Lipid-lowering Therapy

• Registration Number: NCT01867203
• Lead Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Brief Summary

Patients needing lipid lowering therapy will be recruited before initiation of the treatment. For each patient, total and LDL cholesterol levels before start of therapy will be measured. One, three and six months after his/her first visit, when steady-state will be reached, for each included patient, the cholesterol levels will be re-assessed in order to evaluate the response to statin therapy calculated as the amplitude of cholesterol reduction. The aim is to assess the association between patient's genotype and the response to statin therapy.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2013-05-29
• Study First Submitted QC: 2013-05-29
• Study First Posted: 2013-06-03
• Study Start: 2017-08-01
• Primary Completion: 2019-08-01
• Study Completion: 2019-09-01
• Status Verified: 2021-03
• Last Update Submitted: 2021-03-16
• Last Update Posted: 2021-03-18

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Patient known to be compliant
• Age [25-80]
• treated with Atorvastatin, simvastatin, fluvastatin.

Exclusion Criteria

• Pregnancy

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Cholesterol levels-side effects	1 to 6 months

Trial Locations

Locations (1)

Saint-Luc Hospital; 🇧🇪 Brussels, Belgium